Dexcom Alerts: Stolen G7 Glucose Sensors Resold, Posing Infection and Reading Risks
What Happened — Dexcom disclosed that G7 continuous glucose monitoring sensors from two scrapped production lots were stolen and subsequently sold through unauthorized resale channels. The compromised sensors may carry bacterial contamination and can deliver inaccurate glucose readings, creating both health‑and‑safety hazards for end‑users.
Why It Matters for TPRM
- Physical‑device theft introduces a supply‑chain attack vector that bypasses traditional cyber controls.
- Counterfeit or contaminated medical devices can trigger regulatory penalties, liability claims, and brand erosion.
- Third‑party risk programs must extend oversight to logistics, warehousing, and device‑disposal processes.
Who Is Affected — Patients using Dexcom G7 sensors, healthcare providers that prescribe or distribute the devices, and any third‑party logistics partners handling Dexcom inventory.
Recommended Actions —
- Verify the provenance of all Dexcom G7 sensors in inventory; quarantine any units lacking a verifiable chain‑of‑custody.
- Update vendor risk questionnaires to include physical‑security controls, device‑tracking, and disposal procedures.
- Communicate the advisory to clinical staff and patients, advising them to inspect sensors for tampering and to report anomalies.
- Review insurance coverage for product liability related to contaminated medical devices.
Technical Notes — The incident stems from physical theft and unauthorized resale, not a software vulnerability. Risks include bacterial infection from compromised sterility and erroneous glucose readings due to sensor damage. Source: TechRepublic Security